DNA Damage by Tumor Cell-Specific N-Oxides

肿瘤细胞特异性氮氧化物对 DNA 的损伤

基本信息

  • 批准号:
    7016287
  • 负责人:
  • 金额:
    $ 16.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-03-14 至 2008-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): 3-Amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine, TPZ) is a bioreductively-activated DNA-damaging agent that selectively kills the hypoxic cells found in virtually all solid tumors. This compound shows great clinical promise and is currently being examined in more than ten different clinical trials, including several phase III studies. Importantly, TPZ damages DNA via a completely novel sequence of chemical reactions in which the one-electron reduced drug initiates radical-mediated DNA damage and then the drug or its metabolites transfer oxygen atoms from their N-oxide functional groups to the resulting DNA radicals, thus, converting them to strand cleavage sites. While the medicinal properties of TPZ have been extensively investigated, many of its biologically relevant chemical properties remain poorly understood. The growing clinical interest in TPZ provides a practical incentive to characterize the relevant chemistry of this drug. In addition, characterization of this new chemical motif that efficiently delivers cytotoxic DNA-damaging radicals to the interior of hypoxic cells may be of fundamental interest in both medicinal chemistry and toxicology. The work described in this proposal is divided into three Specific Aims: 1. How does TPZ generate radical lesions on DNA? Does the drug serve to deliver the known DNA-damaging agent hydroxyl radical to hypoxic cells? How do the conditions of low oxygen and low pH found in tumor cells combine to facilitate DNA damage by the drug? 2. What is the chemical mechanism by which TPZ and its metabolites transfer oxygen atoms from their N-oxide functional groups to DNA radicals? This unprecedented reaction allows the drug to efficiently damage DNA under hypoxic conditions and may play a central role in defining the structural nature of the final DNA lesions caused by TPZ. 3. We propose studies to characterize the structural nature of the DNA strand breaks and base damage mediated by TPZ. These studies will explore the possibility that the unusual conditions under which TPZ operates, along with the unique chemical properties of the drug, lead to a unique spectrum of DNA lesions that confront cells with social challenges to their DNA-repair systems.
描述(由申请人提供):3-氨基-1,2,4-苯并三嗪1,4-二氧化物(替拉扎明,TPZ)是一种生物还原活化的DNA损伤剂,可选择性杀死几乎所有实体瘤中发现的缺氧细胞。该化合物显示出巨大的临床前景,目前正在十多项不同的临床试验中进行检查,包括几项III期研究。重要的是,TPZ通过一种全新的化学反应序列损伤DNA,其中单电子还原药物引发自由基介导的DNA损伤,然后药物或其代谢物将氧原子从其N-氧化物官能团转移到所得的DNA自由基,从而将其转化为链切割位点。虽然TPZ的药用特性已被广泛研究,但其许多生物学相关的化学特性仍然知之甚少。对TPZ日益增长的临床兴趣为表征该药物的相关化学提供了实际激励。此外,表征这种新的化学基序,有效地提供细胞毒性DNA损伤自由基的内部缺氧细胞可能是根本的兴趣,在药物化学和毒理学。本提案中所述的工作分为三个具体目标:1. TPZ如何在DNA上产生根本性损伤?药物是否用于将已知的DNA损伤剂羟基自由基传递到缺氧细胞?肿瘤细胞中发现的低氧和低pH值的条件如何结合联合收割机以促进药物对DNA的损伤?2. TPZ及其代谢物将氧原子从其N-氧化物官能团转移到DNA自由基的化学机制是什么?这种前所未有的反应使药物能够在缺氧条件下有效地损伤DNA,并可能在确定TPZ引起的最终DNA损伤的结构性质方面发挥核心作用。3.我们建议研究TPZ介导的DNA链断裂和碱基损伤的结构性质。这些研究将探索TPZ在不寻常的条件下运作的可能性,沿着药物独特的化学性质,导致独特的DNA损伤谱,使细胞面临对其DNA修复系统的社会挑战。

项目成果

期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Isotopic labeling experiments that elucidate the mechanism of DNA strand cleavage by the hypoxia-selective antitumor agent 1,2,4-benzotriazine 1,4-di-N-oxide.
  • DOI:
    10.1021/tx400356y
  • 发表时间:
    2014-01-21
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    Shen X;Rajapakse A;Gallazzi F;Junnotula V;Fuchs-Knotts T;Glaser R;Gates KS
  • 通讯作者:
    Gates KS
Synthesis and Crystal Structure of the Azoxydichinyl Helicene, Pyrido[3,2-f]quinolino[6,5-c]cinnoline 5-Oxide Monohydrate.
  • DOI:
    10.1007/s10870-011-0162-z
  • 发表时间:
    2011-11
  • 期刊:
  • 影响因子:
    0.8
  • 作者:
    Rajapakse, Anuruddha;Barnes, Charles L.;Gates, Kent S.
  • 通讯作者:
    Gates, Kent S.
Application of Suzuki-Miyaura and Buchwald-Hartwig Cross-coupling Reactions to the Preparation of Substituted 1,2,4-Benzotriazine 1-Oxides Related to the Antitumor Agent Tirapazamine.
  • DOI:
    10.1002/jhet.2559
  • 发表时间:
    2017-01
  • 期刊:
  • 影响因子:
    2.4
  • 作者:
    Sarkar U;Hillebrand R;Johnson KM;Cummings AH;Phung NL;Rajapakse A;Zhou H;Willis JR;Barnes CL;Gates KS
  • 通讯作者:
    Gates KS
Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs.
  • DOI:
    10.1021/acs.joc.7b03035
  • 发表时间:
    2018-02
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Xiulong Shen;Charles H. Laber;Ujjal Sarkar;F. Galazzi;Kevin M. Johnson;Nathaniel G. Mahieu;Roman Hillebrand;T. Fuchs-Knotts;C. Barnes;G. Baker;K. Gates
  • 通讯作者:
    Xiulong Shen;Charles H. Laber;Ujjal Sarkar;F. Galazzi;Kevin M. Johnson;Nathaniel G. Mahieu;Roman Hillebrand;T. Fuchs-Knotts;C. Barnes;G. Baker;K. Gates
Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2,4-benzotriazine 1,4-dioxide.
  • DOI:
    10.1021/ja8049645
  • 发表时间:
    2009-01-28
  • 期刊:
  • 影响因子:
    15
  • 作者:
    Junnotula, Venkatraman;Sarkar, Ujjal;Sinha, Sarmistha;Gates, Kent S.
  • 通讯作者:
    Gates, Kent S.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kent S Gates其他文献

DNA-catalyzed hydrolysis of DNA phosphodiesters
DNA 催化的 DNA 磷酸二酯水解
  • DOI:
    10.1038/nchembio.224
  • 发表时间:
    2009-10-01
  • 期刊:
  • 影响因子:
    13.700
  • 作者:
    Mostafa I Fekry;Kent S Gates
  • 通讯作者:
    Kent S Gates
FaPy lesions and DNA mutations
法氏囊病变和 DNA 突变
  • DOI:
    10.1038/nchembio.1274
  • 发表时间:
    2013-06-17
  • 期刊:
  • 影响因子:
    13.700
  • 作者:
    Kent S Gates
  • 通讯作者:
    Kent S Gates

Kent S Gates的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kent S Gates', 18)}}的其他基金

Cross-links at abasic sites in duplex DNA
双链 DNA 脱碱基位点的交联
  • 批准号:
    10524017
  • 财政年份:
    2012
  • 资助金额:
    $ 16.62万
  • 项目类别:
Cross-links At Abasic Sites in Duplex DNA
双链 DNA 中无碱基位点的交联
  • 批准号:
    8664848
  • 财政年份:
    2012
  • 资助金额:
    $ 16.62万
  • 项目类别:
Cross-links At Abasic Sites in Duplex DNA
双链 DNA 中无碱基位点的交联
  • 批准号:
    8867233
  • 财政年份:
    2012
  • 资助金额:
    $ 16.62万
  • 项目类别:
Cross-links At Abasic Sites in Duplex DNA
双链 DNA 中无碱基位点的交联
  • 批准号:
    8372731
  • 财政年份:
    2012
  • 资助金额:
    $ 16.62万
  • 项目类别:
Cross-links at abasic sites in duplex DNA
双链 DNA 脱碱基位点的交联
  • 批准号:
    10295786
  • 财政年份:
    2012
  • 资助金额:
    $ 16.62万
  • 项目类别:
Cross-links at abasic sites in duplex DNA
双链 DNA 脱碱基位点的交联
  • 批准号:
    10054954
  • 财政年份:
    2012
  • 资助金额:
    $ 16.62万
  • 项目类别:
Cross-links At Abasic Sites in Duplex DNA
双链 DNA 中无碱基位点的交联
  • 批准号:
    8531243
  • 财政年份:
    2012
  • 资助金额:
    $ 16.62万
  • 项目类别:
Chemical and Biological Mechanisms of Leinamycin
莱纳霉素的化学和生物学机制
  • 批准号:
    7028123
  • 财政年份:
    2006
  • 资助金额:
    $ 16.62万
  • 项目类别:
Chemical and Biological Mechanisms of Leinamycin
莱纳霉素的化学和生物学机制
  • 批准号:
    7286021
  • 财政年份:
    2006
  • 资助金额:
    $ 16.62万
  • 项目类别:
Conference Grant: "DNA Alkylation: From Natural Products to Chemotherapy"
会议资助:“DNA烷基化:从天然产物到化疗”
  • 批准号:
    7159973
  • 财政年份:
    2006
  • 资助金额:
    $ 16.62万
  • 项目类别:

相似海外基金

Thymineless stress, DNA repair and recombination
无胸腺嘧啶应激、DNA 修复和重组
  • 批准号:
    6937205
  • 财政年份:
    2004
  • 资助金额:
    $ 16.62万
  • 项目类别:
DNA Repair-Mediated BCNU Resistance in CNS Tumors
CNS 肿瘤中 DNA 修复介导的 BCNU 耐药性
  • 批准号:
    6963064
  • 财政年份:
    2004
  • 资助金额:
    $ 16.62万
  • 项目类别:
Thymineless stress, DNA repair and recombination
无胸腺嘧啶应激、DNA 修复和重组
  • 批准号:
    6821551
  • 财政年份:
    2004
  • 资助金额:
    $ 16.62万
  • 项目类别:
Thymineless stress, DNA repair and recombination
无胸腺嘧啶应激、DNA 修复和重组
  • 批准号:
    7109312
  • 财政年份:
    2004
  • 资助金额:
    $ 16.62万
  • 项目类别:
MODULATION OF DNA REPAIR TO ENHANCE CHEMOTHERAPY
调节 DNA 修复以增强化疗效果
  • 批准号:
    6563889
  • 财政年份:
    2002
  • 资助金额:
    $ 16.62万
  • 项目类别:
CLINICAL APPLICATIONS OF MODULATION OF DNA REPAIR PATHWAYS
DNA 修复途径调节的临床应用
  • 批准号:
    6563891
  • 财政年份:
    2002
  • 资助金额:
    $ 16.62万
  • 项目类别:
MODULATION OF DNA REPAIR TO ENHANCE CHEMOTHERAPY
调节 DNA 修复以增强化疗效果
  • 批准号:
    6429988
  • 财政年份:
    2001
  • 资助金额:
    $ 16.62万
  • 项目类别:
CLINICAL APPLICATIONS OF MODULATION OF DNA REPAIR PATHWAYS
DNA 修复途径调节的临床应用
  • 批准号:
    6429990
  • 财政年份:
    2001
  • 资助金额:
    $ 16.62万
  • 项目类别:
MODULATION OF DNA REPAIR TO ENHANCE CHEMOTHERAPY
调节 DNA 修复以增强化疗效果
  • 批准号:
    6300580
  • 财政年份:
    2000
  • 资助金额:
    $ 16.62万
  • 项目类别:
CLINICAL APPLICATIONS OF MODULATION OF DNA REPAIR PATHWAYS
DNA 修复途径调节的临床应用
  • 批准号:
    6300582
  • 财政年份:
    2000
  • 资助金额:
    $ 16.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了